These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26038781)

  • 21. Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance.
    Vergison A; Hanquet G
    Pediatr Infect Dis J; 2012 Apr; 31(4):400-3. PubMed ID: 22418653
    [No Abstract]   [Full Text] [Related]  

  • 22. Pneumococcal conjugate vaccine--relevance for developing countries.
    Mulholland K
    Indian Pediatr; 2001 May; 38(5):453-60. PubMed ID: 11359971
    [No Abstract]   [Full Text] [Related]  

  • 23. Understanding the link between pneumococcal serotypes and invasive disease.
    Soley C; Arguedas A
    Vaccine; 2009 Aug; 27 Suppl 3():C19-21. PubMed ID: 19535183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumococcal vaccine for adults.
    Med Lett Drugs Ther; 2012 Oct; 54(1402):87-8. PubMed ID: 23114739
    [No Abstract]   [Full Text] [Related]  

  • 25. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(21):394-5. PubMed ID: 22647745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
    van der Harst S
    Ned Tijdschr Geneeskd; 2007 Aug; 151(33):1853-4; author reply 1854. PubMed ID: 17874645
    [No Abstract]   [Full Text] [Related]  

  • 27. An update on the new pneumococcal conjugate vaccine.
    Holland MJ
    Pediatr Ann; 2001 Sep; 30(9):515-6. PubMed ID: 11554259
    [No Abstract]   [Full Text] [Related]  

  • 28. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Conjugate pneumococcal vaccines in pediatric population: up to date].
    Hausdorff W; Lepetic A; De Antonio R
    Rev Chilena Infectol; 2014 Dec; 31(6):763-4. PubMed ID: 25679940
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose.
    Klugman KP; Madhi SA; Adegbola RA; Cutts F; Greenwood B; Hausdorff WP
    Vaccine; 2011 Apr; 29(18):3372-3. PubMed ID: 21396901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protecting Persons Aged 65 Years and Older Against Pneumococcal Disease.
    Michigan Department of Community Health
    Mich Med; 2015; 114(1):20. PubMed ID: 26489268
    [No Abstract]   [Full Text] [Related]  

  • 34. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.
    Grivea IN; Priftis KN; Giotas A; Kotzia D; Tsantouli AG; Douros K; Michoula AN; Syrogiannopoulos GA
    Vaccine; 2014 Nov; 32(48):6513-20. PubMed ID: 25252194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.
    Kilpi T; Ahman H; Jokinen J; Lankinen KS; Palmu A; Savolainen H; Grönholm M; Leinonen M; Hovi T; Eskola J; Käyhty H; Bohidar N; Sadoff JC; Mäkelä PH;
    Clin Infect Dis; 2003 Nov; 37(9):1155-64. PubMed ID: 14557958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens.
    Mahon BE; Hsu K; Karumuri S; Kaplan SL; Mason EO; Pelton SI; ;
    Vaccine; 2006 Mar; 24(14):2514-20. PubMed ID: 16417951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invasive pneumococcal disease and the need for the new 13-valent pneumococcal vaccine.
    Bolton M; Barson W
    Pediatr Ann; 2010 Aug; 39(8):497-503. PubMed ID: 20704146
    [No Abstract]   [Full Text] [Related]  

  • 38. Update on the recommendations for the routine use of pneumococcal conjugate vaccine for infants. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2006 May; 32(ACS-4):1-6. PubMed ID: 16718922
    [No Abstract]   [Full Text] [Related]  

  • 39. [Serious invasive pneumococcal disease in young children: the importance of vaccination].
    Haveman LM; Geelen SP; Sanders EA; Wolfs TF
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1917-20. PubMed ID: 12404904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
    Ray GT
    Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.